Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetic considerations

D F Volles1, R McGory

  • 1Department of Pharmacy Services, University of Virginia Health System, Charlottesville, USA.

Critical Care Clinics
|February 4, 1999
PubMed
Summary

Pain medication elimination is altered in liver and kidney disease, impacting drug safety. Careful dosing and patient monitoring are crucial for managing pain in critical care patients with organ dysfunction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Hepatitis B immune globulin: the US experience.

Clinical transplantation·2000
Same author

Pharmacoeconomic analysis of HBV liver transplant therapies.

Clinical transplantation·2000
Same author

Stability of cefepime in peritoneal dialysis solution.

The Annals of pharmacotherapy·1999
Same author

Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.

Transplantation·1998
Same author

Establishing an institution-specific therapeutic range for heparin.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Hepatology

Background:

  • Altered drug pharmacokinetics, particularly serum elimination, are observed in hypoperfused or cirrhotic livers.
  • Phase I oxidation-dependent drugs are sensitive to hepatic blood flow, while Phase II glucuronidation-dependent drugs are affected by hepatocyte function.
  • Renal function impairment reduces the elimination of parent drugs and metabolites, potentially leading to toxicity with certain opioids.

Purpose of the Study:

  • To review the pharmacokinetics of pain medications in patients with liver and renal dysfunction.
  • To highlight the clinical implications of altered drug elimination in critical care settings.
  • To provide guidance on judicious pain medication administration in patients with end-stage organ disease.

Main Methods:

  • Review of existing literature on opioid pharmacokinetics in liver and renal disease.
  • Analysis of factors influencing drug metabolism and elimination, including hepatic blood flow and Phase I/II metabolic pathways.
  • Consideration of clinical effects and adverse outcomes in critically ill patients.

Main Results:

  • Opioid elimination pathways are significantly affected by liver and kidney dysfunction.
  • Drugs with short durations of action may accumulate due to prolonged half-lives in end-stage disease.
  • Clinical outcomes are influenced by multiple physiological alterations in critical care patients.

Conclusions:

  • Patients with severe liver and renal dysfunction require cautious administration of pain medications due to metabolic disturbances.
  • Smaller, less frequent doses or alternative administration strategies may be preferable to continuous infusions.
  • Individualized dose titration and vigilant adverse effect monitoring are essential for safe and effective pain management in the ICU.

Related Experiment Videos